
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2015

InfuSystem Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-35020
(Commission
File Number)

20-3341405
(I.R.S. Employer
Identification No.)

31700 Research Park Drive
Madison Heights, Michigan 48071
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (248) 291-1210

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 7.01. Regulation FD Disclosure.

InfuSystem Holdings, Inc. hereby furnishes the information in Exhibit 99.1 hereto, the investor presentation dated April 15, 2015.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 InfuSystem Holdings, Inc. Investor Presentation dated April 15, 2015.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFUSYSTEM HOLDINGS, INC.

By: /s/ Jonathan P. Foster

Name: Jonathan P. Foster

Title: Chief Financial Officer

Dated: April 17, 2015

EXHIBIT INDEX

Exhibit 99.1 InfuSystem Holdings, Inc. Investor Presentation dated April 15, 2015.

InfuSystem Holdings, Inc.

Shareholder Presentation

As of April 15, 2015

Eric Steen – CEO

Jonathan Foster – CFO



Safe Harbor Statement

Certain statements contained in this presentation are forward-looking statements and are based on future expectations, plans and prospects for the business and operations of InfuSystem Holdings, Inc. ("InfuSystem" or "the Company") that involve a number of risks and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to materially differ from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to: potential changes in overall healthcare reimbursement, including CMS competitive bidding; sequestration; concentration of customers; increased focus on early detection of cancer; competitive treatments; dependency on Medicare Supplier Number; availability of chemotherapy drugs; global financial conditions; changes and enforcement of state and federal laws; dependency on suppliers; risks associated with acquisitions and joint ventures, including integration risks; US Healthcare Reform; relationships with healthcare professionals and organizations; technological changes related to infusion therapy; dependency on websites and intellectual property; dependency on key personnel; dependency on banking relationships; risks associated with our common stock, as well as any litigation to which the Company may be subject from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2014 and in subsequent filings made by the Company from time to time with the Securities and Exchange Commission (the "SEC"), which can be obtained via the SEC's Edgar website or by contacting the Company or the SEC. Forward-looking statements in this presentation are made as of April 15, 2015, and, unless required by law, the Company disclaims any duty to supplement, update or revise such statements, whether as a result of subsequent developments, changed expectations or otherwise. The Company regularly posts important information to the investors section of its website.



Summary

InfuSystem is a growing healthcare company that provides infusion pumps and related products and services for patients in the home, in oncology clinics, ambulatory surgery centers, and other sites of care from five locations serving all 50 States and Canada. We deliver improved patient satisfaction and outcomes with world-class quality, both in and out of the home environment. The company's market share and profitable growth is predicated on expansion into new therapies, increased use of electronic connectivity, development of new products and services, and strategic geographic expansion.



InfuSystem - "Infusion Made Easy"

Company Overview

- Provides infusion pumps and related products and services for patients in:
 - The Patient's Home
 - Oncology Clinics
 - Ambulatory Surgery Centers
 - And Other Sites of Care
- Serves all 50 States & Canada
 - from 5 locations
- Improves outcomes and delivers high patient satisfaction with world-class ISO and CHAP accredited quality
- Profitable growth is predicated on:
 - Growth of oncology and orthopedic surgery
 - Increased electronic connectivity
 - New products and services
 - Strategic geographic expansion

Fiscal Year Dec 31, 2014


- Revenues \$66.5M (Up 7%)
- AEBITDA \$16.1M (Up 1%)
- Market Cap \$66.3M @ \$2.95 (as of 4/13/15)



*"The right pump, the right place, and the right time.
Working and patient ready."*


InfuSystem
INFUSION MADE EASY.

InfuSystem Revenue Streams




Revenue Diversification

2009 Revenues \$39M



- Rentals - Colorectal Cancer (A)
- Rentals - Infectious Disease (A,G)
- Rentals - Hospitals/Home Care (G)
- Sales - Equip, Consumables (A,B,G)

2014 Revenues



- Rentals - Other Cancers (A)
- Rentals - Pain Management (A,G)
- Rentals - Service & Repair (B,G)

InfuSystem Provider Niche – Therapy Started in Clinic


\$10 B
Total
Home
Infusion
Market

Chemotherapy at Home

- InfuSystem is the market leader with over 1,600 practice sites served
- Estimated over \$200 M market.
- Cancer rates growing


Nerve Block at Home

- 5.69M orthopedic surgeries annually
- 50% are projected to be Continuous Peripheral Nerve Block Candidates
- Estimated \$700 M market
- Growing therapy

 U.S. Population

3 1 8 , 8 0 2 , 8 9 5

Electronic Connectivity through Electronic Medical Record (EMR) Interface



Lifecycle Management – Infusion Pumps



Total Pump Fleet Management

- Online, Anytime
- Order New Pumps
- Schedule Service & Repair
- Access Recertification Docs

Lifecycle Management – Asset Tracking


Assets by Status



Smart Metrics

Loss Threat Count	11
Loss Threat Percent	3%
Assets Under Par	7
30 Day Average Daily Check-Outs	6

Assets by Model



Overdue Assets



InfuSystem
INFUSION MADE EASY.

High Patient Satisfaction Scores



For Faster Turnaround and Improved Utilization



New Products & Services

- Pain Management Service
- Catheter care kits
- Pole-mounted pump sales and rentals in oncology
- Smart Pump Services
- Infusion disposals including IV administration sets & chemo safety



InfuSystem
INFUSION MADE EASY.

Financial Overview

2015 vs 2014: Increase in G&A expense on IT and Pain Management initiatives of \$0.7 million; a write-off of pumps of \$0.4 million, severance of \$0.2 million.



(1) Free Cash Flow = Adjusted EBITDA less CapEx and Net Purchases of Medical Equipment

Uses of Free Cash Flow

Total Debt



PP&E and Medical Equipment in Service (at cost)



Unrestricted Liquidity



Medical Equipment Turnover Ratio



New \$45 Million Credit Facility

- \$45 million credit facility signed with JPMorgan Chase
 - Term is five years
 - \$10 million revolver – undrawn at close
 - \$27 million Term A Loan – fully drawn at close
 - \$8 million Term B Loan – undrawn drawn at close
 - Expansion capital
- Interest rate drops from 7.75% to 3.0%
 - \$1 million in cash interest savings potential
- Repayment
 - Term A Loan is repaid \$965K quarterly
 - Term B Loan is repaid quarterly as a percent of the drawn ranging from 3.75% to 4.475%
- Favorable covenants and terms
 - Leverage ratio maximum increased from 2.0x to 3.0x
 - Fixed charge ratio minimum decreased from 1.75x to 1.25x

CHASE 

InfuSystem[®]
INFUSION MADE EASY.

InfuSystem[®]
INFUSION MADE EASY.

Positioned For Growth

Market Trends

- InfuSystem is uniquely positioned to take efficient advantage of growing market trends in...
- Oncology
- Orthopedic surgery
- Growth of home infusion

Leadership

- Experienced Medical Industry Executives
- Focused on improving patient satisfaction and outcomes
- Supported by World Class - ISO and CHAPS Accredited - facilities and motivated employee

Strategy

- Increased use of electronic connectivity
- Expanding geographic footprint
- Expanding into new therapies, products and services



Where Does This Take INFU?

- Aging Population and Cancer Growth
- More Patients Home IV , Commercial Pay
Recognizing Value, CMS Competitive Bidding
- Peripheral Nerve Block and Smart Pump Growth
- Revenue Growth in High Single Digits Through 2015



Thank You for Your Interest!

IR Contact Info:

Joe Dorame
Managing Partner
Lytham Partners, LLC
602-889-9700
dorame@lythampartners.com

